A phase 2b/3 randomized, double-blind, placebo-controlled, parallel group, multicenter protocol to evaluate the efficacy and safety of Icotrokinra in participants with moderately to severely active Crohn's Disease

Start Date01 Nov 2025

Sponsor / Collaborator

Janssen-Cilag International NV

NCT07196722

/ RecruitingPhase 2/3

A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

Start Date03 Oct 2025

Sponsor / Collaborator

Janssen Research & Development LLC

NCT07196748

/ RecruitingPhase 3

A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults With an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult and adolescent participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops tiny open ulcers).

Start Date01 Oct 2025

Sponsor / Collaborator

Janssen Research & Development LLC

100 Clinical Results associated with Icotrokinra

100 Translational Medicine associated with Icotrokinra

100 Patents (Medical) associated with Icotrokinra

Literatures (Medical) associated with Icotrokinra

25 Nov 2025·NEJM evidence

Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites

Article

Author: Ceitlin, Raul Hernan Gabriel ; Weirich, Oliver ; Bissonnette, Robert ; Huang, Yu-Huei ; Hoffmann, Matthias ; Warren, Richard B. ; DeKlotz, Cynthia M. C. ; Lain, Edward ; Song, Eingun James ; Li, Shu ; Hsu, Ming-Chun ; Lynde, Charles W. ; Nunes, Fabio ; Rubens, Jessica H. ; Ota, Takayuki ; DeLozier, Amy M. ; Gooderham, Melinda

BACKGROUND:

Plaque psoriasis involving high-impact sites is difficult to treat. Icotrokinra, a targeted oral peptide that selectively binds interleukin-23 receptors, is a new treatment being investigated for this condition.

METHODS:

This phase 3, double-blind, placebo-controlled trial randomly assigned participants 12 years of age and over with plaque psoriasis {with a body surface area ≥1%; an Investigator's Global Assessment (IGA) score ≥2 [clear (0), minimal (1), mild (2), moderate (3), and severe (4)] for overall skin; and at least moderate psoriasis involving the scalp, genitalia, and/or hands and feet} to receive either icotrokinra 200 mg daily or placebo in a 2:1 ratio. The primary end point at week 16 was the proportion of participants achieving an overall IGA score of 0 or 1 and an improvement of 2 points or more from baseline (IGA score of 0 or 1), reported as the between-group difference adjusted for high-impact site involvement, geographic region, and body surface area category using Mantel-Haenszel weights. Absent/clear or minimal/almost clear scalp, genital, and/or hand and foot psoriasis at 16 weeks were secondary end points. Adverse events were recorded.

RESULTS:

The trial randomly assigned 311 participants (icotrokinra, n=208; placebo, n=103) with scalp (n=252: icotrokinra, n=167; placebo, n=85), genital (n=140: icotrokinra, n=98; placebo, n=42), and/or hand and foot (n=71: icotrokinra, n=48; placebo, n=23) psoriasis. The proportions of participants achieving an IGA score of 0 or 1 in the icotrokinra and placebo groups were 56.7% and 5.8%, respectively [adjusted difference, 51.1 percentage points; 95% confidence interval (CI), 42.1 to 58.8; P<0.001]. The proportions of icotrokinra-treated and placebo-treated participants achieving absence/clear or minimal/almost clear high-impact site psoriasis were as follows: scalp, 65.9% and 10.6% (difference, 55.5 percentage points; 95% CI, 44.8 to 64.4; P<0.001); genitalia, 76.5% and 21.4% (difference, 55.4 percentage points; 95% CI, 39.1 to 68.0; P<0.001); and hand and foot, 41.7% and 26.1% (difference, 16.7 percentage points; 95% CI, -6.2 to 36.8; P=0.144). Adverse events occurred among 50% and 42% of participants in the icotrokinra and placebo groups, respectively.

CONCLUSIONS:

At 16 weeks, significantly higher proportions of participants 12 years of age and over with at least moderate psoriasis involving high-impact sites treated with icotrokinra versus placebo achieved clearance or minimal psoriasis in their skin overall and in the scalp and genital areas, but not in their hands and feet. No safety signals were identified. (Funded by Johnson & Johnson; ClinicalTrials.gov number, NCT06095102.).

06 Nov 2025·NEW ENGLAND JOURNAL OF MEDICINE

Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents

Article

Author: Soung, Jennifer ; Pink, Andrew E. ; Lebwohl, Mark G. ; Shi, Yuling ; DeKlotz, Cynthia M.C. ; Jiang, Jingzhi ; Bissonnette, Robert ; Miller-Kassamali, Megan ; Cafone, Joseph ; Wang, Wen-hui ; Hebert, Adelaide A. ; Moore, Angela Y. ; Li, Shu ; Nunes, Fabio ; Pinter, Andreas ; Toth, Darryl P.

BACKGROUND:

Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the treatment of plaque psoriasis.

METHODS:

We conducted a phase 3, double-blind, randomized, placebo-controlled trial involving adults and adolescents (≥12 years of age) with moderate-to-severe plaque psoriasis, as defined by all the following: a total body-surface area of psoriasis involvement of at least 10%, a Psoriasis Area and Severity Index (PASI) score of at least 12 (range, 0 to 72, with higher scores indicating a greater extent or severity of psoriasis), and an Investigator's Global Assessment (IGA) score of at least 3 (range, 0 [clear skin] to 4 [severe disease]). Participants were assigned in a 2:1 ratio to receive icotrokinra at a dose of 200 mg once daily through week 24 or placebo through week 16 followed by transition to icotrokinra. The coprimary end points were an IGA 0/1 response (IGA score of 0 or 1 with ≥2-point reduction from baseline) and a PASI 90 response (≥90% reduction from baseline in the PASI score) at week 16.

RESULTS:

A total of 684 participants underwent randomization (456 to the icotrokinra group and 228 to the placebo group). At week 16, a total of 65% of the participants receiving icotrokinra and 8% of those receiving placebo had an IGA 0/1 response, and 50% and 4%, respectively, had a PASI 90 response (P<0.001 for both comparisons). Complete clearance of skin at week 16 was significantly more likely with icotrokinra than with placebo (IGA score of 0, 33% vs. 1%; PASI 100 response [100% reduction from baseline in the PASI score], 27% vs. <1%; P<0.001 for both comparisons). The percentage of participants with at least one adverse event through week 16 was 49% in each group; the most common adverse events in each group were nasopharyngitis and upper respiratory tract infection. The exposure-adjusted incidence of adverse events was consistent through week 24.

CONCLUSIONS:

Selective blockade of the interleukin-23 receptor with the targeted oral peptide icotrokinra resulted in a significantly higher incidence of skin clearance at week 16 than placebo among adults and adolescents with moderate-to-severe plaque psoriasis. Longer-term data will provide a more complete understanding of the benefit-risk profile of icotrokinra. (Funded by Johnson & Johnson; ICONIC-LEAD ClinicalTrials.gov number, NCT06095115.)See also in NEJM Evidence: Targeted Oral Peptide Icotrokinra for Psoriasis Involving High‑Impact Sites.

01 Sep 2025·Dermatology and Therapy

Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling

Article

Author: Patel, Shefali ; Shi, Yifan ; Baguet, Tristan ; Ndifor, Anthony ; Wang, Jianyao ; Somani, Sandeep ; Sensenhauser, Carlo ; Park, Seonghee ; Adriaenssen, Lieve ; Leclercq, Laurent ; Fourie, Anne ; Mardirosian, Saro ; Monshouwer, Mario ; Chaudhuri, Siladitya Ray ; Dallas, Shannon ; Knight, Beverly ; Sukumaran, Siddharth ; Polidori, David ; Patch, Raymond ; Sun, Chengzao ; DiLoreto, Karen ; Barros, Stephanie A ; Tammara, Brinda ; Geist, Brian ; Modi, Nishit B ; Moss, Darren ; Laenen, Aline

INTRODUCTION:

Icotrokinra (formerly JNJ-77242113 or PN-21235) is a targeted oral peptide that selectively inhibits interleukin-23 receptor signaling. The studies described here assessed its absorption, distribution, metabolism, and excretion (ADME), and potential for drug-drug interactions (DDI).

METHODS:

In vitro assays evaluated permeability, plasma protein binding, blood-to-plasma partitioning, metabolic stability, and interactions with drug transporters and metabolic enzymes. The nonclinical pharmacokinetic properties of icotrokinra were studied in vivo in rats and monkeys. Phase 1 studies evaluated the pharmacokinetic profile, metabolic profile and excretion in healthy volunteers.

RESULTS:

Icotrokinra demonstrated oral bioavailability of 0.1-0.3% in animals, with evidence of systemic pharmacodynamic activity, without the use of an absorption enhancer. The compound was stable across species in plasma, gastrointestinal matrices, and hepatocytes. Protein binding was low across species (~ 50% in human plasma), and icotrokinra distributed freely to tissues, including skin, joints, and gastrointestinal tissues. Following oral dosing in both rats and monkeys, fecal excretion of unabsorbed drug was the primary elimination route, and metabolite levels were low (each < 2% of dose) in plasma and excreta, with unchanged icotrokinra being the main circulating component. Icotrokinra was neither a substrate nor an inhibitor of prototypical drug transporters or cytochrome P450 enzymes. Icotrokinra exhibited dose-proportional pharmacokinetics from 25 mg to 1000 mg in a first-in-human study, and no serious adverse events were identified following single and multiple dose administrations. Unchanged icotrokinra was the only drug-related component in human plasma.

CONCLUSIONS:

Icotrokinra exhibited high stability and an ADME profile consistent with that of a small peptide, with no risk of DDI identified on the basis of in vitro studies. Clinical data demonstrated linear pharmacokinetics and no major metabolites.

TRIAL REGISTRATION NUMBER:

ClinicalTrials.gov, NCT04621630. Euclinicaltrials.eu, EUCT: 2023-504720-26-00. A Graphical Abstract is available for this article.

177

News (Medical) associated with Icotrokinra

07 Jan 2026

·www.fiercepharma.com

Lilly's prospective cardiometabolic launches dominate list of drugs to watch in 2026: Clarivate

Eli Lilly's anticipated launches of two cardiometabolic medicines stand out in Clarivate's Drugs to Watch report for 2026. Johnson & Johnson also has two drugs on this year's list. Eli Lilly has dominated headlines in recent months, recently taking the crown as the most valuable company in the biopharma industry by market cap. And the song remains much the same in analytics firm Clarivate's Drugs to Watch 2026 report.The annual outlook, which identifies (PDF) 11 potential blockbusters and transformative medicines, highlights two cardiometabolic treatments from the Indianapolis company, which have yet to be approved but could ultimately take the place of its current cash cows Mounjaro and Zepbound.Lilly’s investigational treatments are daily GLP-1 pill orforglipron, which is slated for an FDA decision by March of this year, and triple-action, weekly injection retatrutide, which Clarivate expects will be ready for launch in 2028.Both assets are under development in obesity, diabetes and a host of other related indications. The Clarivate analysts project that orforglipron will generate a whopping $11.1 billion in obesity sales and $5.2 billion in diabetes sales in 2031, though the forecasts partially overlap due to shared populations. Retatrutide is expected to deliver $10 billion in obesity revenue and $20 billion in diabetes revenue, again with some overlap between estimates.Clarivate’s report highlights the continued ascent of the obesity and metabolic disease market, as well as how Lilly has positioned itself to take full advantage. Morgan Stanley projects the overall cardiometabolic medicine market will reach $150 billion by 2035.“The GLP-1 receptor agonist (RA) revolution is entering a new phase of maturation and diversification,” Clarivate wrote. “Orforglipron and retatrutide exemplify the next generation of metabolic therapies: oral formulations that promise improved adherence, triple-hormone mechanisms that deliver superior weight loss and expanded therapeutic applications spanning from brain health to renal disease.” As for the 2031 sales projections of the drugs on Clarivate’s 2026 list, orforglipron and retatrutide eclipse all others. The remaining medicines Clarivate highlighted have much lower sales projections than Lilly's, with no others expected to surpass the $2-billion threshold in 2031, according to Clarivate’s reckoning.Johnson & Johnson is the only other company with two drugs named—bladder cancer treatment Inlexzo, which gained FDA approval in September of last year, and immunotherapy icotrokinra, which Clarivate expects will be launched this year. The analysts project 2031 sales of the duo at $1.8 billion and $1.5 billion, respectively.Inlexzo made the grade with Clarivate for its bladder-sparing, “paradigm-shifting” drug-releasing system, which allows for extended release of the chemotherapy gemcitabine directly to patients' bladders through an intravesical system that can be placed in minutes in an outpatient setting.Icotrokinra, meanwhile, is poised to become the first-to-market targeted oral peptide designed to block the interleukin (IL)-23 receptor, which plays a key role in the inflammatory process in moderate-to-severe plaque psoriasis as well as ulcerative colitis, Clarivate said.Clarivate also singled out two protein degrader cancer drugs, including BeOne Medicine’s BGB-16673. The once-daily oral treatment is set for a potential launch in 2027 and has the potential to become a “paradigm-changing treatment for B-cell malignancies,” the report notes. The asset could be effective at treating multiple hematological cancers as well, according to the analysts. Clarivate projects the drug's sales at $1.2 billion in 2031.The other protein degrader on Clarivate's radar is Bristol Myers Squibb’s mezigdomide, which is expected to launch in 2026 and could generate $1.5 billion in 2031. The oral second-generation cereblon E3 ligase modulator could be a new option for patients with relapsed or refractory multiple myeloma who've previously been treated with immunomodulatory drugs, Clarivate said.Yet another oncology drug on the list comes in the form of Celcuity’s gedatolisib, which is set up for launch this year and is expected to deliver $1.1 billion in sales in 2031.Clarivate also selected Otsuka’s voyxact, which is expected to launch in 2026 and generate $955 million in 2031 sales. The first-in-class selective A proliferation-inducing ligand (APRIL) inhibitor could serve as a “high-impact, disease-modifying entrant" in IgA nephropathy (IgAN), also known as Berger’s disease, the Clarivate team predicts. The analytics team made another rare disease pick in GSK’s Exdensur, which was approved in December and is expected to generate sales of $510 million in 2031. The monoclonal antibody, which targets IL-5, is the first approved ultra-long-acting biologic with a six-month dosing schedule for severe asthma, providing greater convenience over currently available IL-5 inhibitors that require monthly or bimonthly dosing. Also on Clarivate’s list are two drugs that recently suffered untimely rejections from the FDA. Sanofi’s multiple sclerosis treatment tolebrutinib is a potential first-in-class, brain-penetrant Bruton tyrosine kinase (BTK) inhibitor. But its prospects have been dampened by both efficacy and safety concerns raised in an FDA complete response letter (CRL).Corcept Therapeutics’ Cushing syndrome drug relacorilant also was hit with an unexpected CRL from the U.S. regulator last month, with the agency suggesting it did not have enough information from the company to make a benefit-risk assessment of the treatment. That medication is also due for an FDA decision in platinum-resistant ovarian cancer this July, Clarivate pointed out.

Drug ApprovalBiosimilar

07 Jan 2026

·www.biospace.com

Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026

NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026 in San Francisco, CA. The Company will also participate in one-on-one meetings. 44th Annual J.P. Morgan Healthcare Conference - January 12-15, 2026 Format: Company Presentation Day/Time: Tuesday, January 13 at 8:15 AM PST Webcast: If you are interested in meeting with the Protagonist team during the conference, please reach out to your J.P. Morgan representative. A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event. About Protagonist Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with a New Drug Application (NDA) for icotrokinra submitted to the FDA in July, and an NDA for rusfertide submitted in December 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R"), which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program. More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at . Investor Relations Contact Corey Davis, Ph.D. LifeSci Advisors cdavis@lifesciadvisors.com Media Contact Virginia Amann ENTENTE Network of Companies virginiaamann@ententeinc.com SOURCE: Protagonist Therapeutics View the original press release on ACCESS Newswire

License out/inPhase 3NDA

06 Jan 2026

·www.fiercebiotech.com

Alumis beams as pivotal data on Sotyktu rival drive stock surge

Alumis plans to file for FDA approval of its TYK2 inhibitor in the back half of 2026.\n A pair of phase 3 psoriasis studies of Alumis’ TYK2 inhibitor have hit their primary endpoints, setting the biotech up to file for approval of a potential challenger to Bristol Myers Squibb’s Sotyktu. With the news, Alumis’ shares more than doubled in premarket trading. The biotech tested its TYK2 inhibitor, envudeucitinib, in two studies that collectively enrolled more than 1,700 adults with moderate to severe plaque psoriasis. About half of the participants received Alumis’ oral drug candidate twice daily. The other half of the patients were split up to receive either apremilast, which Amgen sells as Otezla, or placebo. On average across the two trials, 74% of people on envudeucitinib experienced at least a 75% improvement in their symptoms, as measured on the Psoriasis Area and Severity Index (PASI), at Week 16. Alumis said 59% of patients scored zero or one on the static Physician’s Global Assessment (sPGA) at Week 16. The PASI 75 and sPGA results met the trials’ co-primary endpoints.At Week 24, 65% of patients experienced at least a 90% improvement on the PASI. Alumis reported “clear separation from placebo” on PASI 90 as early as Week 4. More than 40% of patients met the PASI 100 criteria by Week 24, indicating that they had completely clear skin. Alumis also said it saw clinically meaningful improvements in patient-reported outcomes related to quality of life and itch. BMS reported PASI 75 response rates of 53% and 58% at Week 16 in the phase 3 trials quoted (PDF) on the Sotyktu label. At Week 24, the proportion of patients achieving PASI 90 on Sotyktu ranged from 32% to 42%. BMS reported PASI 100 results in 10% to 14% of patients in the two Sotyktu studies. With the caveat that cross-trial comparisons can be unreliable, the results appear to favor Alumis\' envudeucitinib over Sotyktu. The envudeucitinib results look to be in line with the expectations Alumis CEO Martin Babler set at an investor event in September. Noting that Alumis saw a 64% placebo-adjusted PASI 75 at Week 12 of a phase 2 trial, Babler said a result in the 50% to 60% range at Week 16 would be competitive. Alumis’ phase 3 release lacks results from the placebo arm. Between 9% and 13% of patients on placebo in BMS’ Sotyktu trials met the PASI 75 criteria at Week 16.With no new safety signals emerging in its phase 3 trials, Alumis plans to file for FDA approval in the back half of 2026. FDA approval could add to the pressure on Sotyktu, which generated $206 million for BMS over the first nine months of 2025 and has underperformed prelaunch expectations. Envudeucitinib is on course to come to market after icotrokinra, the oral IL-23 blocker Johnson & Johnson is lining up as a challenger to Sotyktu. J&J filed for FDA approval in adults and adolescents with plaque psoriasis in July. Icotrokinra performed similarly to envudeucitinib in two phase 3 trials, racking up PASI 75 rates of 74% and 77% at Week 16.While J&J could be a tough competitor, the psoriasis market’s size, fragmentation and level of treatment switching mean there is room for multiple big products. Alumis plans to focus on the efficacy, safety and convenience of envudeucitinib as it tries to carve out a piece of the market. In parallel, the biotech will work to validate its molecule in lupus, where potentially pivotal phase 2b data are due this year.In premarket trading Tuesday, Alumis\' shares were up 115% to nearly $18 from a Monday closing price of $8.31.

Phase 3Clinical ResultDrug ApprovalPhase 2

100 Deals associated with Icotrokinra

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plaque psoriasis	NDA/BLA	United States	Johnson & Johnson	21 Jul 2025
Crohn Disease	Phase 3	United States	Janssen Pharmaceutica NV	03 Oct 2025
Crohn Disease	Phase 3	United States	Janssen Research & Development LLC	03 Oct 2025
Crohn Disease	Phase 3	China	Janssen Research & Development LLC	03 Oct 2025
Crohn Disease	Phase 3	Japan	Janssen Pharmaceutica NV	03 Oct 2025
Crohn Disease	Phase 3	Japan	Janssen Research & Development LLC	03 Oct 2025
Crohn Disease	Phase 3	Argentina	Janssen Pharmaceutica NV	03 Oct 2025
Crohn Disease	Phase 3	Argentina	Janssen Research & Development LLC	03 Oct 2025
Crohn Disease	Phase 3	Australia	Janssen Pharmaceutica NV	03 Oct 2025
Crohn Disease	Phase 3	Australia	Janssen Research & Development LLC	03 Oct 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05223868 (FRONTIER 1, CTgov)	Phase 2	Plaque psoriasis	255	placebo+JNJ- 77242113 (Placebo)	fnhpvoxqko = eorvxvgrpn tfkgzjlkpl (gvkfoyzbpd, txnmqxazgx - qylrfpqvah) View more	-	30 Dec 2025
				JNJ-77242113 (JNJ-77242113 25 mg QD)	fnhpvoxqko = lnyehisiik tfkgzjlkpl (gvkfoyzbpd, rwtqlxfipr - eoyttclyxy) View more
NCT06095102 (ICONIC-TOTAL, Pubmed \| NEJM Evid) Manual	Phase 3	Psoriasis	311	Icotrokinra 200 mg daily	pndbbxvvkd(ybwrtfsuhb) = qdvruhmktl krrgkmsiuj (rqglqtlnja ) View more	Positive	05 Nov 2025
				Placebo	pndbbxvvkd(ybwrtfsuhb) = ytquxpevgt krrgkmsiuj (rqglqtlnja ) View more
NCT06049017 (ANTHEM-UC, Company_Website) Manual	Phase 2	Colitis, Ulcerative	-	Icotrokinra 400 mg once daily	tyoddeouhz(tmmxiusuik) = Similar proportions of pts reported AEs and SAEs through Week 28 across all icotrokinra dose groups and the placebo group. gmwwqujwiw (disxnllnla )	Positive	27 Oct 2025
				Placebo
NCT06095102 (ICONIC-TOTAL, ACR2025) Manual	Phase 3	Plaque psoriasis	311	Icotrokinra 200 mg	sotxijoeig(rltowxltam) = faulijstau gfuqxihlxg (ntqeedudyu ) Met View more	Positive	24 Oct 2025
				Placebo	sotxijoeig(rltowxltam) = iqwjkccihk gfuqxihlxg (ntqeedudyu ) Met View more
NCT06095102 (ICONIC-TOTAL, Company_Website) Manual	Phase 3	Psoriasis	-	Icotrokinra	fztmfdrgbr(anreokaehg) = oxrbkhljrj jhviksihom (szuzakfnti ) View more	Positive	24 Oct 2025
NCT06095115 (ICONIC-LEAD, ACR2025)	Phase 3	Plaque psoriasis	684	Icotrokinra 200 mg	osgogfyviw(pomajutibv) = jlrgnzvotz spjkrihtyw (tdcdrkmdeb ) View more	Positive	24 Oct 2025
				Placebo	osgogfyviw(pomajutibv) = yehkyzymml spjkrihtyw (tdcdrkmdeb ) View more
FRONTIER 1 (ACR2025)	Phase 2	Arthritis, Psoriatic β-Defensin-2 (BD-2) \| IL-22 \| IL-17A ... View more	23	Icotrokinra (ICO)	bzreqgcyaa(sfvcgummsj) = jpzremyvvm tvzusoihsk (hhlfmyhjmp ) View more	Positive	24 Oct 2025
				Placebo	vtmulqvvnk(bvhhpajodu) = jfprxpuugo ngevwrshnb (jtgegkpame ) View more
NCT06049017 (ANTHEM-UC, Company_Website) Manual	Phase 2	Colitis, Ulcerative	-	Icotrokinra 400 mg QD	ddlnhetmyj(prwmszlwmp) = iollvlqhsj xipstgylvw (mpvkkosude ) Met View more	Positive	07 Oct 2025
				Icotrokinra 200 mg QD	ddlnhetmyj(prwmszlwmp) = latwpftpie xipstgylvw (mpvkkosude ) Met View more
NCT06095115 (ICONIC-LEAD, PRNewswire) Manual	Phase 3	Plaque psoriasis	-	Icotrokinra (re-randomized at Week 24)	rlnhtvwmta(xqpyburrgn) = utlzkqlpuy eykgjgbovk (ezqrqukaro )	Positive	17 Sep 2025
				Placebo (re-randomized at Week 24)	rlnhtvwmta(xqpyburrgn) = agwtkjescx eykgjgbovk (ezqrqukaro )
NCT06220604 \| NCT06143878 (ICONIC-ADVANCE 2, PRNewswire) Manual	Phase 3	Plaque psoriasis	-	Icotrokinra	ggqacinqdv(lnggsahivv) = Icotrokinra showed superior skin clearance vs placebo (Week 16) and deucravacitinib (Weeks 16 and 24). gwfldyjlqj (dsfdzkodfg ) Met View more	Superior	17 Sep 2025
				Deucravacitinib

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis